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Background. Although the apolipoprotein (APOE)–4 allele has been shown to determine the outcome of sev-
eral infections, its relationship with cytomegalovirus (CMV) has not been explored. We examine whether APOE
determines CMV and herpes simplex virus type 1 (HSV-1) antibody levels and assess whether C-reactive protein
(CRP) mediates any observed relationships.
Methods. We conducted a cross-sectional analysis of a randomly selected subset (n  1561/1789) of partici-
pants aged 60 –101 in the Sacramento Area Latino Study on Aging. Blood samples were tested for APOE genotype,
CRP, and immunoglobulin G antibodies to CMV and HSV-1. Multivariate logistic regression was used to examine the
association between 4 and CMV and HSV antibody levels. We also assessed whether CRP mediates the effects of any
observed associations between 4 and viral antibody levels.
Results. CMV antibody and CRP levels varied significantly by APOE genotype. The association between CRP and
CMV antibody was strengthened in the presence of 4. In contrast, this effect was not observed in HSV-1. We found
that APOE-4 carriers had significantly lower levels of CRP yet significantly higher levels of CMV antibodies, sug-
gesting a mediating pathway.
Conclusions. APOE-4 carriers may experience immunological aberrations that lead to lower levels of CRP and
correspondingly higher CMV antibody levels.
Apolipoprotein E (APOE) is a 299-aa protein involved
in the packaging of cholesterol and other lipids. Three
APOE alleles, APOE-2, -3, and -4 (henceforth re-
ferred to as 2, 3, and 4, respectively), give rise to 3
protein isoforms, apoE2, apoE3, and apoE4, which have
different affinities to lipoprotein receptors. The 4 allele
has been shown to determine the outcome of several
infections, including herpes simplex virus type 1 (HSV-
1), hepatitis C virus (HCV), HIV, and Chlamydia pneu-
moniae [1– 6]. For example, HIV-infected individuals
possessing the 4 allele had increased oxidative stress of
the central nervous system and were twice more likely to
have dementia than HIV-positive individuals without
4 allele [2, 3]. In other studies, the presence of 4 was
significantly more frequent among HSV-1–seropositive
individuals with cold sores than were HSV-1–seroposi-
tive individuals without cold sores [5, 7]. On the other
hand, possessing an 4 allele may be protective against
liver damaged caused by HCV [1, 6].
C-reactive protein (CRP) is an important component
of the innate immune system, in which it acts as an op-
sonin and activates the classical complement pathway
[8, 9]. A high CRP response plays a protective role
against active bacterial and viral infections and also been
found to be moderately elevated in the presence of per-
sistent herpesvirus infections [10 –15]. Several recent
studies [16 –18] have indicated that the presence of any
4 allele is associated with lower levels of CRP and that
the levels vary depending on the 4 allele combination.
The present study sought to examine whether APOE
genotype influences antibody response to herpesvirus
infections (HSV-1 and cytomegalovirus [CMV]) in a
large, elderly, community-based sample of individuals
Received 19 April 2007; accepted 6 July 2007; electronically published 5
December 2007.
Potential conflicts of interest: none reported.
Financial support: National Institute of Aging, National Institutes of Health (NIH;
grant AG12975 to M.N.H.); National Institute of Diabetes and Digestive and Kidney
Diseases, NIH (grant NIH5P60 DK60753 to M.N.H.); Chemistry Core of the Mich-
igan Diabetes Research and Training Center (grant NIH5P60 DK20572 to M.N.H.);
Robert Wood Johnson Health and Society Scholars Program at the University of
Michigan (grant 045823 to fund the viral testing to A.E.A.); University of Michigan–
Medical School, Institute of Gerontology (fellowship support support to A.E.A.).
Reprints or correspondence: Dr. Allison E. Aiello, Assistant Prof. of Epidemiol-
ogy, Dept. of Epidemiology, Center for Social Epidemiology and Population Health,
University of Michigan School of Public Health, 3659 SPH Tower, 109 Observatory,
Ann Arbor, MI 48109-2029 (aielloa@umich.edu).
The Journal of Infectious Diseases 2008; 197:34 – 41
© 2007 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2008/19701-0007$15.00
DOI: 10.1086/524144
M A J O R A R T I C L E
34 ● JID 2008:197 (1 January) ● Aiello et al.
of Mexican origin. In addition, we assess whether the relation-
ship between 4 and antibody response to herpesvirus infections
is mediated by CRP.
METHODS
Study design. The study subjects were derived from the Sac-
ramento Area Latino Study on Aging (SALSA), an ongoing pro-
spective cohort study of Mexican Americans aged 60 –100 (in
1998/1999) living in the community. From the overall SALSA
cohort (n  1789), we drew a subpopulation of 1561 subjects
who had available results for CMV, HSV-1, APOE, and CRP
testing. The details of the SALSA study have been discussed else-
where [19]. All study subjects signed an informed consent form,
and the study was approved by the Institutional Review Board at
the University of Michigan.
Baseline data collection for the SALSA study began in 1998,
with a 2-h interview of participants in their homes. Information
on lifestyle, health, duration, date of diagnoses for 35 health con-
ditions, and demographic factors were collected during the par-
ticipant interviews.
Laboratory analyses. The level (expressed as optical density
units) of IgG reactive to HSV-1 and CMV in aliquots of contin-
uously frozen (70°C) serum samples was assessed using a com-
mercially available ELISA IgG detection system (Wampole Lab-
oratories). In accordance with the manufacturer’s instructions,
samples were analyzed for the level of IgG antibody signal as
expressed by the mean optical density value. The sensitivity and
specificity of the assay for HSV-1 are reported to be 97.1% and
96.8%, respectively; for CMV, the sensitivity and specificity are
reported to be 96.4% and 93.3%, respectively. Each 96-well com-
mercial ELISA kit contained controls and internal calibrations.
CRP was analyzed using the CRP Ultra Wide Range Reagent
Kit latex-enhanced immunoassay (Equal Diagnostics). The
manufacturer’s instructions were followed, and CRP levels were
determined using an automated analyzer and a prepared calibra-
tion curve. With the highly sensitive method, the kit provides a
range of measurable CRP from 0.05 to 80.0 mg/L. When results
fell outside of the range, samples were diluted, retested, and mul-
tiplied by the dilution factor.
The 1513 samples for APOE genotyping were obtained from
serum samples for 1122 participants and from buccal cell swabs
for 391 participants. DNA was extracted using the PureGene
DNA Extraction Kit (Gentra Systems), and APOE genotype was
determined by polymerase chain reaction amplification fol-
lowed by restriction enzyme digestion (HhaI), as described else-
where [20]. Allele frequencies are as follows: 2, 4.30%
(n  130); 3, 88.50% (n  2678); and 4, 7.20% (n  218).
The APOE genotype was in Hardy-Weinberg equilibrium.
Statistical analyses. To compare means, t tests were used;
to compare proportions, 2 or Fisher’s exact tests were used.
Measured CRP levels in milligrams per liter were skewed, so a
natural logarithmic transformation (ln-CRP) was applied to
maintain a normal distribution. We graphed the means and SEs
of antibody levels and ln-CRP levels by different APOE geno-
type, to assess how genotype affects these levels.
Next, APOE genotype was categorized as any 4 (2/4, 3/4,
and 4/4) allele versus all other alleles (2/3 and 3/3). General
linear models were used to assess the relationship between 4
status and CMV antibody levels, HSV-1 antibody levels, and
ln-CRP levels. Logistic regression was used to assess the effect of
CRP on antibody levels (CMV and HSV-1) after adjusting for
age and sex. Other covariates including place of birth, education,
the number of health conditions (diabetes mellitus, hyperten-
sion, myocardial infarction, angina pectoris, heart failure, atrial
fibrillation, rheumatic fever/heart valve problem, cancer, and
stroke) and body mass index (BMI) were assessed as potential
confounders. Confounding may be present when the following
criteria are met: (1) the covariate is related to the outcome of
interest; (2) the distribution of the covariate is significantly dif-
ferent among the exposure groups; (3) and the covariate is not
hypothesized to be in the pathway between the exposure and the
outcome of interest. Correspondingly, t tests and 2 tests were
used to examine whether each of the covariates was associated
with ln-CRP levels and whether the distribution of the covariates
varied by any 4 allele versus all other alleles and by levels of
antibody to each of the viruses (HSV-1 and CMV). None of the
baseline health covariates met the criteria and therefore were not
included in the final models. Sex met the criteria of a confounder
and was included in the final models. Although age did not meet
all of the criteria of confounding, it was included in the final
models because age is known to be associated with CRP levels,
APOE distribution, and CMV.
We explored the possible mediation effects of CRP on the
relationship between 4 and antibody levels by use of the steps
suggested by Baron and Kenny [21]. A factor that represents a
step in the hypothesized pathway linking an exposure/trait (car-
riage of 4) and an outcome (CMV IgG levels) is considered an
“intermediate” factor that “mediates” the relationship between
the 2 variables. Further discussion regarding mediation and test-
ing for mediation has been discussed by Shrout and Bolger [22].
Briefly, these steps involved 3 models to assess (1) the correlation
between 4 and CMV levels, (2) the correlation between 4 and
CRP levels, and (3) the effect of CRP on CMV levels controlling
for 4. We also used the  coefficients (slope) and SEs from the
models for 2 and 3 above to conduct a Sobel test for mediation.
All analyses were conducted using procedures in SAS (version
9.1; SAS Institute).
RESULTS
Demographic characteristics. The demographic characteris-
tics of subjects who were included in the analyses (n  1561) are
shown in table 1, stratified by sex. There were no differences in
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age, place of birth (Mexico or other Latin American country vs.
United States), and number of baseline health conditions be-
tween males and females. Overall, the proportion of those with
any 4 was 13.7% (207/1513), and the proportion with no 4 was
86.3% (1306/1513). The proportion of 3/3 genotype was signif-
icantly higher among females than males, and 3/4 was signifi-
cantly higher among males than females. None of the other ge-
notypes showed significant sex differences. The differences in
proportions between male and female in terms of education
were significant for grade level beyond fourth grade, with more
women with highest level of education under the 11th grade and
more men completing at least the 12th grade and beyond. There
was a higher proportion of men who had a BMI between 25 and
30, whereas women had higher proportion with the highest BMI
level (30).
Using the clinical cut point designated by the ELISA test kits,
97% (1507/1560) of the study subjects showed signs of prior
infection with CMV, and 98% (1528/1560) showed signs of
prior infection with HSV-1. Mean levels of CMV and HSV-1 IgG
antibodies and ln-CRP are shown in table 2. Women had signif-
icantly higher mean levels of CMV IgG antibodies than men
(P  .0001). In contrast, there was no difference between mean
levels of HSV-1 IgG comparing males and females (P  .4930).
More than 50% of the study subjects had CRP levels in the high-
est category, and CRP levels varied significantly by sex
(P  .0001)
Effects of APOE on infections and CRP. The levels of CMV,
HSV-1 IgG antibodies, and CRP varied with APOE genotype
(see figure 1). The variability pattern of CRP diverged from
those of CMV and HSV-1 antibody levels. Subjects who were
homozygous for 4 had high levels of CMV and HSV-1 anti-
bodies but low levels of CRP; however the standard errors
were high. Participants with 2/3 or 3/3 had low levels of
CMV and HSV-1 antibodies but correspondingly higher lev-
els of CRP.
We also assessed variability by any 4 status (homozygous or
heterozygous) versus all other alleles (figure 2). Individuals with
at least one 4 allele had significantly higher levels of CMV an-
tibodies yet significantly lower levels of CRP than did subjects
without an 4 allele. Although there were similar observed pat-
terns in HSV-1 antibody by 4 allele status, the variability was
not statistically significant.
Table 1. Descriptive statistics for the Sacramento Area Latino Study on Aging cohort analysis sample.
Characteristic
Total sample




Age at baseline, mean  SD, yearsb 70.5  7.0 70.7  7.2 70.2  6.8 .19
Place of birth Mexico or other
Latin American country, %c 49.30 51.04 46.81 .10
No. of baseline health conditions,
mean  SDd 1.3  1.1 1.31  1.2 1.4  1.1 .34
APOE genotype, %e
2/3 7.90 8.00 7.77 .87
2/4 0.73 0.79 0.65 .75
3/3 78.42 80.29 75.73 .03
3/4 12.22 10.47 14.72 .01
4/4 0.73 0.45 1.13 .13
Any 4 13.70 11.71 16.50 .008
Education, %
Grade 0–3 31.15 31.72 30.33 .56
Grade 4–11 38.29 40.50 35.15 .03
Grade 12 30.57 27.77 34.53 .004
LDLC, mg/dL . . . 123.93  35.2 121.97  33.5 .54
BMI, %f
25 20.18 21.29 18.62 .20
25–30 38.48 35.12 43.19 .0013
30 41.34 43.59 38.18 .03
NOTE. APOE, apolipoprotein; BMI, body mass index; LDLC, low-density lipoprotein cholesterol.
a t tests and 2 tests were conducted to assess whether sex differences were statistically significant.
b Information on age at baseline was not available for 7 individuals.
c Information on place of birth was not available for 7 individuals.
d Total no. of health conditions included reported diabetes mellitus, hypertension, myocardial infarction, angina pectoris, heart
failure, atrial fibrillation, rheumatic fever/heart valve problem, cancer, and stroke.
e Information on APOE genotype was not available for 48 individuals.
f Information on BMI was not available for 25 individuals.
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Association between CRP and 4 with antibody levels.
Individuals with CRP levels above the median value had signifi-
cantly higher levels of CMV antibody, adjusting for age and sex
(table 3). The odds ratio for HSV-1 was also elevated but not statis-
tically significant. The association between CRP and CMV antibody
levels increased by 2-fold in the presence of at least one 4 allele. The
interaction term between CRP and 4 also shows a trend indicating
a stronger association with increased levels of CMV antibody but
was of borderline statistical significance (P  .051). Higher levels
of CRP were not associated with higher levels of HSV-1 antibody
levels, nor did 4 increase the association to a significant level.
CRP mediation of 4 and CMV. Figure 3 shows the results
of linear regression models used to assess possible CRP media-
tion of 4 and CMV relationship. Each path on the diagram
represents the standardized  coefficient for the following rela-
tionships: (1) between 4 and CRP, (2) between CRP and CMV,
(3) between 4 and CMV, (4) between 4 and CMV adjusted for
CRP (estimate in parentheses). The estimate in parentheses
shows that, after adjusting for CRP, the relationship between 4
and CMV antibody levels is significantly increased. Conducting
the Sobel test for mediation on the results shown in figure 3
yielded z  -2.83 and P  .005, suggesting significant media-
tion by CRP.
DISCUSSION
This is the first study of which we are aware to demonstrate that
APOE is significantly associated with variability in CMV anti-
body levels. It is also the first study to demonstrate that, through
its suppressive effects on CRP, 4 is related to higher levels of
circulating CMV IgG antibody, even after controlling for age
and sex. In contrast, variability in HSV-1 IgG antibody levels by
APOE status was not statistically significant.
Most of the earlier research on the relationship between 4
and infection has focused on HSV-1 [23–25], but a few other
pathogens, such as HIV, HCV, and malarial parasites, have also
Table 2. Levels of cytomegalovirus (CMV) antibodies, herpes simple virus type 1 (HSV-1) anti-
bodies, and proportions of C-reactive protein (CRP) among study subjects.
Category
Total sample
(n  1561) Female (n  911) Male (n  643)
P (male/female
difference)a
Virus IgG antibody levels
CMV, mean  SD 4.98  2.04 5.36  1.95 4.45  2.02 .0001
HSV-1, mean  SD 6.55  2.24 6.51  2.14 6.59  2.36 .49
ln-CRP levels, mean  SD 1.11  1.20 1.32  1.16 0.80  1.20 .0001
ln-CRP levels, %b
Low (1) 18.42 13.08 25.97 .0001
Medium (1–3) 28.65 26.04 32.35 .0068
High (3) 52.93 60.88 41.68 .0001
NOTE. ln-CRP, natural log of CRP.
a t tests and 2 tests were conducted to assess whether sex differences were statistically significant.
b Information on ln-CRP levels was not available for 8 individuals.
Figure 1. Apolipoprotein (APOE) genotypes and levels of cytomegalo-
virus (CMV) IgG antibodies, herpes simple virus type 1 (HSV-1) IgG
antibodies, and C-reactive protein (CRP). Means and SEs of levels of CMV
and HSV-1 IgG antibodies and the natural log of CRP (ln-CRP) were
calculated and plotted by APOE genotype.
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been examined [1, 3, 6, 26]. Wozniak et al. [26] have suggested
that APOE may compete with these pathogens for entry into
cells because these pathogens also use the same cell-entry medi-
ators as those of APOE, such as surface-binding heparan sul-
phate proteoglycans (HSPG) and/or low-density lipoprotein re-
ceptors. A recent mouse study by Miller and Federoff supports
such a proposed pathway for HSV-1 by demonstrating that car-
riage of 4 in the presence of HSV-1 renders cells more vulner-
able to lytic infection and possibly apoptosis than do other alleles
(2 or 3) [27]. HSPG engagement is also integral to CMV entry
[28]. Therefore, it is possible that a similar relationship exists
between CMV and APOE during cellular entry processes.
It has also been suggested that differing structures of the
APOE genotypes may lead to variations in binding affinity for
pathogen-specific cellular entry sites or receptors, ultimately in-
fluencing entry, spread, cellular damage, or even protection
from pathogens [26]. For example, 4 appears to determine the
outcome of HSV-1 infection, whereas 2/4 and 2/3 are protec-
tive for HCV and 2/2 appears to be a risk factor for malarial
infection at an earlier age of onset [1, 5, 6, 23–25, 29]. Corre-
spondingly, we observed that CMV antibody levels varied within
the 4-positive group, with 3/4 having the lowest CMV anti-
body levels, whereas 4/4 and 2/4 had similar CMV antibody
levels. This variability pattern was unique to CMV. For HSV-1,
the highest antibody levels were seen in 4/4, whereas 3/4 and
2/4 had comparable antibody levels. Further studies assessing
how variations in isoform-binding affinities may influence CMV
pathogen cellular entry, spread, and damage are warranted.
We observed not only that the higher levels of CRP were as-
sociated with higher levels of CMV but that this association was
strengthened in the presence of at least one 4 allele, even though
levels of CRP among 4-positive subjects was lower compared
with non-4 alleles. 4 carriers with high CRP levels were more
than twice as likely to have high CMV levels than were non-4
carriers with high CRP levels, after adjusting for age and sex.
CMV entry is associated with activation of the innate immune
system, and infection is a strong trigger of antipathogen re-
sponse, including heightened levels of interleukin (IL)– 6, which
modulates CRP activation [30]. Persistent CMV IgG seroposi-
tivity in adults and/or elderly persons has been associated with
higher levels of IL-6 and CRP, suggesting that these infection
may elicit a persistent low-level inflammatory response [12–15,
31]. Recent studies have shown that primary astrocytes in mice
expressing 4 had significantly lower secretion of both tumor
necrosis factor (TNF)– and IL-6 compared with other APOE
isoforms after lipopolysaccharide (LPS) activation [32]. The op-
posite relationship, however, has been reported in a mouse
model examining LPS stimulation of macrophages, whereby
mice with 4 had higher levels of TNF- and IL-6 [33]. Further
research is needed to examine whether APOE determines the
levels of IL-6 in human populations and whether this accounts
for the variability in CRP antibody levels that we and other re-
searchers have observed aging study populations [16 –18].
CRP in the pathway between 4 and CMV. Our media-
tion model demonstrated that CRP is a significant mediator of
the relationship between 4 and CMV antibody levels. 4 is neg-
atively associated with CRP, yet CRP was positively associated
with CMV levels. It is likely that the relationship between 4 and
CMV antibody levels was reduced in the presence of CRP be-
cause mediation can occur in the case when the mediator (CRP)
acts as a pathway-suppressor variable [34]. The adjustment for
CRP in step 3 of the mediation analysis suppresses (removes) the
unwanted variance in 4 and thus uncovered a stronger relation-
ship between 4 and CMV. The influence of 4 appears to be
specific to CMV, because our data showed that 4 and CRP did
not have the same effects on HSV-1 antibody levels. We did not
find any significant effect of CRP on HSV-1 levels, whether in-
dependently or when stratified by 4 status.
Figure 2. Apolipoprotein (APOE)–4 and levels of cytomegalovirus
(CMV) IgG antibodies, herpes simple virus type 1 (HSV-1) IgG antibodies,
and C-reactive protein (CRP). General linear models were used to gen-
erate least-square means of levels of CMV and HSV-1 IgG antibodies and
natural log of CRP (ln-CRP) stratified by any apolipoprotein 4 (homozy-
gous or heterozygous for the 4 allele) vs. no 4 (2/3 and 3/3).
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Before examining mediation, we also explored the effect of 4
and CRP interaction on CMV and HSV-1 antibody levels. The
interaction term did not have a statistically significant effect on
levels of CMV or HSV-1 antibodies. This interaction might be
biologically plausible and have an effect specific to CMV anti-
body levels, as indicated by the trend shown in our data (table 3).
However, our study did not have enough power to test for this
interaction for HSV-1 or CMV given the small number of 4
carriers (n  207). Further research should explore interactions
between 4 and CRP on the effect of these herpesvirus antibody
levels in larger cohorts.
Our study sample consisted of elderly Mexican Americans. As
shown in NHANES III, Mexican Americans have a significantly
higher prevalence of CMV infection (81.7%) than do non-
Hispanic white persons (51.2%) and non-Hispanic black per-
sons (75.8%) [35]. Furthermore, CMV seroprevalence also in-
creased with age: 90.8% in those aged 80 years [35]. Thus, our
study population would be expected to have a higher CMV se-
roprevalence than the general population, which may have en-
hanced the associations we observed.
Our analysis is cross-sectional, where genotype, levels of per-
sistent virus antibody levels, and expression of biomarkers were
measured at the same time. This limited our ability to assess the
temporal relationship between CRP and antibody levels. Given
the mediation effect of CRP on the relationship between 4 and
CMV IgG antibody levels, we would expect low levels of CRP to
precede an increase in CMV IgG antibody levels. However, a
prospective study design is needed to test this hypothesis. We
assessed antibody levels in a population-based study of individ-
uals living in the community setting. Our findings do not reflect
clinical infection; therefore, it is unclear what these relationships
imply for clinically apparent infection with HSV-1 and CMV.
This study demonstrates an association with concurrent persis-
tent CMV IgG antibody levels. For these reasons, it is not possi-
ble to evaluate whether the differences in IgG reflect heightened
risk of subclinical reactivation of the virus among 4 carriers.
Clinical implications. The tripartite relationship of APOE,
CRP, and CMV might play a role in predicting several health
conditions, including susceptibility to HIV-associated CMV in-
fection, dementia, and cardiovascular diseases. CMV is among
Table 3. Association between C-reactive protein (CRP) and apolipo-
protein (APOE)–4 on cytomegalovirus (CMV) and herpes simplex virus
type 1 (HSV-1) antibody levels.
Category
Odds ratio (95% CI)
CMV HSV-1
High ln-CRPa,b 1.398 (1.071–1.824) 1.226 (0.938–1.603)
High ln-CRP among hetero/
homozygous 4 onlyc 2.736 (1.352–5.535) 1.803 (0.918–3.542)
High ln-CRP among non-4c 1.328 (0.983–1.794) 1.153 (0.852–1.560)
ln-CRP  4d 2.133 (0.997–4.563) 1.470 (0.715–3.026)
NOTE. Logistic regression was used to assess the independent effect of high
levels of the natural log of CRP (ln-CRP) on levels of CMV and HSV-1 for all subjects,
which was then stratified by APOE-4 status. All models were adjusted for age and
sex.
a High ln-CRP refers to ln-CRP values above the second quartile.
b Model: logit (probability of high antibody levels among subjects hetero/homozy-
gous 4 only)  0  1  high ln-CRP  2  age  3  sex.
c Same model as b but among non-4 subjects only.
d Interaction between CRP and 4; model: logit (probability of high antibody levels)
 0  1  high ln-CRP  2  4  3  age  4  sex  5  high ln-CRP 
4. Odds ratio of the interaction term  exp(maximum likelihood estimate); 95%
confidence interval (CI)  exp(maximum likelihood estimate  1.96  SE).
Figure 3. C-reactive protein (CRP) as a mediator of the relationship
between apolipoprotein (APOE)–4 and cytomegalovirus (CMV) antibody
levels. Linear regression models were used to assess the following path
associations: (1) the relationship between 4 and CRP, (2) the relation-
ship between CRP and CMV, (3) the relationship between 4 and CMV,
and (4) the relationship between 4 and CMV adjusting for CRP (estimate
in parentheses). Each estimate along the path represents the standard-
ized  coefficient from the linear regression model. The bottom path
estimate in parentheses shows that, after adjusting for CRP, the rela-
tionship between 4 and CMV antibody levels is significantly increased.
Conducting the Sobel test for mediation on the results shown in figure 3
yielded z  -2.83 and P  .005, suggesting significant mediation by
CRP. All models were adjusted for age and sex. *P  .05.
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the most important opportunistic infections in HIV-positive pa-
tients. It is related to numerous conditions in this group, includ-
ing ocular CMV disease, immune reconstitution syndrome, gas-
trointestinal disease, encephalitis and pneumonia, and mortality
[36]. Furthermore, there is increasing evidence of an association
between the presence of 4 and enhanced risk of HIV-related
dementia [3, 37, 38]. Our results suggest that 4 is a factor that
influences CMV IgG antibody levels. Therefore, it is important
to assess whether HIV-infected patients who are 4 carriers are
at an even greater risk for CMV-associated conditions and mor-
tality.
The presence of 4 has also been associated with increased risk
of cognitive decline [39], dementia [40 – 42], and Alzheimer dis-
ease in animal models [43, 44]. Most work supports the notion
that individuals who are heterozygous for 4 (2/4, 3/4) have
an increased risk of AD and vascular dementias and worse cog-
nitive impairment than do those who do not carry any 4 allele
[42, 43]. Individuals who are homozygous for 4 (4/4) are at
even higher risk for these impairments [45, 46]. Our earlier work
has shown that CMV significantly influences the rate of cogni-
tive decline among aging individuals [12]. CRP has also been
implicated as a risk factor for cognitive decline and dementia,
and CRP appears to interact with 4 to enhance the risk of de-
mentia [18]. Further research is necessary to examine how the
complex relationship between 4, CRP, and infection might in-
fluence dementia and other chronic health conditions. Last,
both CRP and CMV appear to aggravate atherosclerosis in
APOE knockout mice [47, 48]. Thus, further studies are needed
to assess whether the CRP-mediated influence of 4 on antibody
levels is also implicated in atherosclerosis given the suggested
roles of persistent CMV in this disease [41].
Conclusion. Our results underscore the important effects of
APOE and CRP on CMV antibody levels. Because CMV anti-
body levels varied significantly by APOE genotype, it is possible
that 3 alleles had different effects on the virus due to isoform
structural differences. This is also the first study of which we are
aware to demonstrate that CRP mediates the relationship be-
tween 4 and CMV antibody levels. This mediation may suggest
that 4 subjects experience differential immune responsiveness
to persistent infection with CMV. The results provide strong
justification for further research into APOE-immunity-
herpesvirus interactions.
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